Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Average Target Price from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $28.83.

Several brokerages recently issued reports on IMNM. Piper Sandler decreased their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Finally, Stephens initiated coverage on Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 target price for the company.

Insider Buying and Selling at Immunome

In other news, CTO Philip Tsai bought 21,000 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was acquired at an average cost of $9.43 per share, for a total transaction of $198,030.00. Following the purchase, the chief technology officer now owns 21,000 shares of the company’s stock, valued at approximately $198,030. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Clay B. Siegall purchased 66,057 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $9.54 per share, with a total value of $630,183.78. Following the acquisition, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at $4,633,511.22. This trade represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 102,862 shares of company stock worth $978,045. Insiders own 8.60% of the company’s stock.

Institutional Trading of Immunome

A number of hedge funds have recently made changes to their positions in IMNM. Lord Abbett & CO. LLC increased its holdings in shares of Immunome by 4.1% in the third quarter. Lord Abbett & CO. LLC now owns 450,280 shares of the company’s stock valued at $6,583,000 after purchasing an additional 17,566 shares during the last quarter. Barclays PLC grew its stake in Immunome by 125.9% in the 3rd quarter. Barclays PLC now owns 105,886 shares of the company’s stock valued at $1,547,000 after buying an additional 59,016 shares during the last quarter. Geode Capital Management LLC raised its holdings in Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after acquiring an additional 144,557 shares during the period. XTX Topco Ltd acquired a new stake in Immunome during the third quarter worth approximately $363,000. Finally, Wellington Management Group LLP lifted its position in Immunome by 137.1% during the third quarter. Wellington Management Group LLP now owns 140,690 shares of the company’s stock worth $2,057,000 after acquiring an additional 81,354 shares during the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $10.97 on Friday. Immunome has a 52 week low of $8.97 and a 52 week high of $30.96. The company has a 50 day moving average price of $12.14 and a two-hundred day moving average price of $13.33. The company has a market capitalization of $684.71 million, a PE ratio of -1.35 and a beta of 1.83.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.